📷 Image: Wikimedia Commons / A.Savin
Business
Bombay High Court reprimands Maharashtra FDA over enforcement actions, alerts businesses
✍️ Livemint
🗓 30 Aug 2026, 10:03 PM
👁 5
The Bombay High Court has criticised the Maharashtra Food and Drug Administration for overstepping its authority in recent enforcement actions, issuing directives that affect businesses across the state.
The Bombay High Court has issued a judgment rebuking the Maharashtra Food and Drug Administration (FDA) for its recent enforcement actions against several enterprises. The court noted that the regulator proceeded without issuing proper notices and appeared to exceed the powers granted under the law.
In its order, the bench directed the state FDA to strictly follow procedural safeguards, ensure that affected parties receive a fair hearing, and revisit pending cases in line with statutory requirements.
The ruling carries immediate implications for businesses operating in Maharashtra, prompting them to review compliance measures and seek legal advice to avoid future disputes.
Legal analysts say the decision highlights the necessity for regulatory agencies to balance public health objectives with due process, ensuring that enforcement actions are both justified and transparent.
Stakeholders are now watching closely as the FDA prepares to implement the court’s directives, which could reshape the regulatory landscape for the state's commercial sector.
In its order, the bench directed the state FDA to strictly follow procedural safeguards, ensure that affected parties receive a fair hearing, and revisit pending cases in line with statutory requirements.
The ruling carries immediate implications for businesses operating in Maharashtra, prompting them to review compliance measures and seek legal advice to avoid future disputes.
Legal analysts say the decision highlights the necessity for regulatory agencies to balance public health objectives with due process, ensuring that enforcement actions are both justified and transparent.
Stakeholders are now watching closely as the FDA prepares to implement the court’s directives, which could reshape the regulatory landscape for the state's commercial sector.